A Real-world Study of Ibrutinib and Venetoclax (I+V) First-Line Treatment Given for Fixed-duration of Time in Participants With Chronic Lymphocytic Leukemia
Clinical trial NCT07602088 · RECRUITING
Trial details
- NCT number
- NCT07602088
- Sponsor
- Janssen Research & Development, LLC
- Status
- RECRUITING
- Study type
- OBSERVATIONAL
- Start date
- 2026-05-18
- Primary completion
- 2029-01-30
- Enrollment
- 60
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.